Drug Profile
ASP 0777
Alternative Names: ASP0777Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma US
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 01 Aug 2013 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
- 17 Nov 2011 Astellas Pharma completes a phase I trial in Alzheimer's disease in USA (NCT01406145)
- 22 Sep 2011 Astellas Pharma completes enrolment in its phase Ib trial for Alzheimer's Disease in USA (NCT01406145)